Jun 11, 2026 02:20AM

Mar 26, 2026 09:32AM

Mar 26, 2026 08:53AM

Feb 15, 2026 07:10PM

Jun 1, 2024 08:17PM

Jan 2, 2022 07:00PM

Dec 22, 2021 08:05AM Ligand Pharma (LGND) Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab for First-Line Treatment of Advanced NSCLC in Combination with Chemotherapy

Dec 22, 2021 08:00AM

Dec 21, 2021 03:44AM

Jul 26, 2021 06:00AM

Jun 21, 2021 08:07AM

Jun 21, 2021 08:03AM

May 28, 2021 06:00AM

May 27, 2021 08:10PM CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application

Oct 26, 2020 07:23PM

Sep 25, 2020 06:00AM

Aug 30, 2020 11:15PM

Aug 18, 2020 09:27PM

Aug 7, 2020 08:38AM

Aug 7, 2020 08:30AM

Apr 23, 2020 12:45AM CStone announces acceptance of its first New Drug Application in mainland China by the National Medical Products Administration, for the first-in-class precision therapy avapritinib in two gastrointes

Apr 22, 2020 08:57PM

Mar 27, 2020 02:02AM

Mar 26, 2020 07:30AM

Mar 26, 2020 06:25AM

Jan 23, 2020 07:03PM

Jan 6, 2020 08:00AM

Dec 10, 2019 09:38PM CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST

Nov 19, 2019 10:30PM

Aug 26, 2019 03:50AM

Aug 22, 2019 11:24PM

Aug 22, 2019 11:21PM

Aug 13, 2019 12:21AM

Jul 22, 2019 12:17AM

Jul 9, 2019 10:23PM CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST

Jun 5, 2019 07:56AM

Jun 2, 2019 11:45PM

May 23, 2019 06:01AM

Apr 15, 2019 02:32AM

Apr 4, 2019 11:44AM

Mar 25, 2019 03:14AM

Mar 21, 2019 09:32AM CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)

328,599 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All